Previous studies targeting CEACAM6 have shown promising results in disrupting tumor cell adhesion, promoting apoptosis, and overcoming chemoresistance mechanisms in preclinical pancreatic cancer models. This evidence concerns the gene CEACAM6 and pancreatic neoplasm.